COSCIENS Biopharma Inc - התחייבויות לטווח ארוך של החברה CSCI

COSCIENS Biopharma Inc. (CSCI) develops orphan drugs, monetizing its intellectual property through licensing agreements with global behemoths to generate royalties without the capital expenditures associated with manufacturing plants. This chart reflects the asset value fixed at 0.00. The business relies on expansion in Latin America and Canada, growing its portfolio of ophthalmology and oncology treatments by acquiring rights from biotech startups.

Long-term debt reflects the aggregate of obligations with a maturity exceeding one year, determining the sustainability of financial leverage. This metric measures a business's ability to service capital expenditures without the risk of default. By analyzing the firm's long-term borrowing values on GURU.Markets, an investor assesses the pace of credit load accumulation. For COSCIENS Biopharma Inc. (CSCI), this indicator is critical when scaling its licensing model in Latin America. Debt optimization confirms the effectiveness of the exclusive partnership strategy with global biopharma.